idarucizumab
E861730
Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
All labels observed (1)
| Label | Occurrences |
|---|---|
| idarucizumab canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T10401936 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: idarucizumab Context triple: [dabigatran, hasReversalAgent, idarucizumab]
-
A.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
avelumab
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
-
D.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
-
E.
Dupixent
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: idarucizumab Target entity description: Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
-
A.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
avelumab
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
-
D.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
-
E.
Dupixent
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
- F. None of above. chosen
Statements (52)
| Predicate | Object |
|---|---|
| instanceOf |
antidote
ⓘ
biologic medicinal product ⓘ dabigatran reversal agent ⓘ monoclonal antibody fragment ⓘ |
| doesNotReverse | other anticoagulants ⓘ |
| hasAdministrationForm | concentrate for solution for infusion ⓘ |
| hasAdverseEffect |
delirium
ⓘ
headache ⓘ hypersensitivity reactions ⓘ hypokalemia ⓘ thromboembolic events ⓘ |
| hasApprovalBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| hasATCCode | V03AB38 ⓘ |
| hasBindingAffinity | very high affinity for dabigatran ⓘ |
| hasCASNumber | 1458672-75-9 ⓘ |
| hasContraindication | known hypersensitivity to idarucizumab or excipients ⓘ |
| hasDeveloper | Boehringer Ingelheim ⓘ |
| hasEffectOnCoagulation | normalizes coagulation tests prolonged by dabigatran ⓘ |
| hasEffectOnLaboratoryParameter |
reduces activated partial thromboplastin time
ⓘ
reduces diluted thrombin time ⓘ reduces ecarin clotting time ⓘ |
| hasEMAAuthorizationYear | 2015 ⓘ |
| hasFDAApprovalYear | 2015 ⓘ |
| hasGenericName | idarucizumab ⓘ |
| hasHalfLife | approximately 45 minutes ⓘ |
| hasIndication |
life-threatening bleeding in patients treated with dabigatran
ⓘ
reversal of dabigatran anticoagulation ⓘ urgent surgery or emergency procedures in patients treated with dabigatran ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMechanismOfAction |
binds dabigatran with high affinity
ⓘ
neutralizes anticoagulant effect of dabigatran ⓘ |
| hasMolecularTargetClass | direct thrombin inhibitor dabigatran ⓘ |
| hasMolecularType | humanized monoclonal antibody fragment ⓘ |
| hasOnsetOfAction | within minutes ⓘ |
| hasPharmacodynamicProperty | does not have intrinsic procoagulant activity ⓘ |
| hasPharmacologicalClass |
hemostatic agent
ⓘ
specific dabigatran reversal agent ⓘ |
| hasPregnancyCategory | insufficient human data ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| hasStorageCondition | refrigerated ⓘ |
| hasTarget |
dabigatran
ⓘ
dabigatran acylglucuronide metabolites ⓘ |
| hasTradeName | Praxbind ⓘ |
| hasUNII | W391YH69L8 ⓘ |
| hasUsualDose | 5 g total dose ⓘ |
| hasUsualDoseRegimen | two consecutive 2.5 g intravenous infusions ⓘ |
| isAdministeredAs |
intravenous bolus
ⓘ
intravenous infusion ⓘ |
| isEliminatedBy | renal excretion ⓘ |
| isIndicatedForPopulation | adult patients ⓘ |
| isUsedFor | rapid reversal of dabigatran effects ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: idarucizumab Description of subject: Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.